Broadfin Capital’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Broadfin Capital’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,127,200	Closed	-$7.54M	–	61
2017 Q2	$7.54M	Hold	1,127,200	–	–	0.92%	30
2017 Q1	$4.38M	Hold	1,127,200	–	–	0.53%	37
2016 Q4	$4.21M	Buy	1,127,200 +109,945	+11%	+$454K	0.47%	49
2016 Q3	$4.22M	Buy	1,017,255 +17,255	+2%	+$81.8K	0.38%	58
2016 Q2	$4.64M	Hold	1,000,000	–	–	0.45%	50
2016 Q1	$3.3M	Buy	1,000,000 +278,405	+39%	+$908K	0.32%	57
2015 Q4	$2.46M	Buy	+721,595	New	+$2.85M	0.15%	78

Broadfin Capital's NVET Position: Q3 2017 in Review

Broadfin Capital sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 1,127,200 shares — an estimated $7.54M sold.

Broadfin Capital first reported a position in NVET in Q4 2015 and held it in 7 quarters. The position peaked at $7.54M in Q2 2017. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

Broadfin Capital reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Broadfin Capital sold 1,127,200 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $7.54M.
Broadfin Capital first reported a position in Nexvet Biopharma plc Ordinary Shares in Q4 2015 and held it in 7 quarters.
Broadfin Capital's Nexvet Biopharma plc Ordinary Shares position peaked at $7.54M in Q2 2017.
0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.